Research Analysts Offer Predictions for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the year. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business’s revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.40) earnings per share.

Several other analysts have also recently issued reports on the stock. StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $25.25.

ACADIA Pharmaceuticals Stock Up 7.1 %

ACADIA Pharmaceuticals stock opened at $19.08 on Thursday. The company has a fifty day simple moving average of $17.26 and a 200-day simple moving average of $16.59. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of 24.46 and a beta of 0.37. ACADIA Pharmaceuticals has a 52-week low of $14.15 and a 52-week high of $29.29.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 10,329 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $173,630.49. Following the sale, the chief operating officer now directly owns 62,105 shares in the company, valued at $1,043,985.05. This represents a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark C. Schneyer sold 10,259 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the transaction, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. The trade was a 16.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,661 shares of company stock worth $414,551. Insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC boosted its position in ACADIA Pharmaceuticals by 5.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 14,770 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 778 shares during the period. Quest Partners LLC boosted its holdings in ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in ACADIA Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares in the last quarter. Park Place Capital Corp acquired a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $25,000. Finally, Values First Advisors Inc. acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at about $27,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.